ELCC 2017: Immunotherapy Advances in the Treatment of NSCLC

Speaker: Naiyer Rizvi

Naiyer Rizvi describes how transformative immunotherapy has been for the care of NSCLC patients in the last 1-2 years. 

He explains how the advances in first and second-line treatment of Lung cancer are leading to clinical practice changes. He points out how a better understanding of selection criteria now allows us to predict which patients may benefit the most from new therapies with durable response. He gives an overview of current research and future treatment opportunities.

Discussion Points

  1. Where do we stand regarding immunotherapy clinical application in NSCLC in the first half of 2017?
  2. Does immunotherapy apply for all NSCLC patients?
  3. What are the advances in first and second line combination therapies?
  4. What current research can bring in the future?